vs
AVANOS MEDICAL, INC.（AVNS）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是RESOURCES CONNECTION, INC.的1.5倍（$180.9M vs $117.7M），AVANOS MEDICAL, INC.净利率更高（-0.7% vs -10.8%，领先10.0%），AVANOS MEDICAL, INC.同比增速更快（0.7% vs -19.2%），AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $15.6M），过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs -11.8%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
AVNS vs RGP — 直观对比
营收规模更大
AVNS
是对方的1.5倍
$117.7M
营收增速更快
AVNS
高出19.9%
-19.2%
净利率更高
AVNS
高出10.0%
-10.8%
自由现金流更多
AVNS
多$5.7M
$15.6M
两年增速更快
AVNS
近两年复合增速
-11.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $117.7M |
| 净利润 | $-1.3M | $-12.7M |
| 毛利率 | 47.5% | 37.1% |
| 营业利润率 | 1.4% | -10.3% |
| 净利率 | -0.7% | -10.8% |
| 营收同比 | 0.7% | -19.2% |
| 净利润同比 | 99.7% | 81.6% |
| 每股收益（稀释后） | $-0.02 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRGP
| Q4 25 | $180.9M | $117.7M | ||
| Q3 25 | $177.8M | $120.2M | ||
| Q2 25 | $175.0M | $139.3M | ||
| Q1 25 | $167.5M | $129.4M | ||
| Q4 24 | $179.6M | $145.6M | ||
| Q3 24 | $170.4M | $136.9M | ||
| Q2 24 | $171.7M | $148.2M | ||
| Q1 24 | $166.1M | $151.3M |
净利润AVNSRGP
| Q4 25 | $-1.3M | $-12.7M | ||
| Q3 25 | $-1.4M | $-2.4M | ||
| Q2 25 | $-76.8M | $-73.3M | ||
| Q1 25 | $6.6M | $-44.1M | ||
| Q4 24 | $-397.3M | $-68.7M | ||
| Q3 24 | $4.3M | $-5.7M | ||
| Q2 24 | $1.8M | $10.5M | ||
| Q1 24 | $-900.0K | $2.5M |
毛利率AVNSRGP
| Q4 25 | 47.5% | 37.1% | ||
| Q3 25 | 48.4% | 39.5% | ||
| Q2 25 | 52.6% | 40.2% | ||
| Q1 25 | 53.6% | 35.1% | ||
| Q4 24 | 54.6% | 38.5% | ||
| Q3 24 | 54.5% | 36.5% | ||
| Q2 24 | 55.7% | 40.2% | ||
| Q1 24 | 57.1% | 37.0% |
营业利润率AVNSRGP
| Q4 25 | 1.4% | -10.3% | ||
| Q3 25 | 0.1% | -1.7% | ||
| Q2 25 | -42.6% | -47.0% | ||
| Q1 25 | 6.1% | -38.4% | ||
| Q4 24 | -233.0% | -52.7% | ||
| Q3 24 | 7.0% | -3.5% | ||
| Q2 24 | 3.7% | 7.6% | ||
| Q1 24 | 2.4% | 2.8% |
净利率AVNSRGP
| Q4 25 | -0.7% | -10.8% | ||
| Q3 25 | -0.8% | -2.0% | ||
| Q2 25 | -43.9% | -52.6% | ||
| Q1 25 | 3.9% | -34.0% | ||
| Q4 24 | -221.2% | -47.2% | ||
| Q3 24 | 2.5% | -4.2% | ||
| Q2 24 | 1.0% | 7.1% | ||
| Q1 24 | -0.5% | 1.7% |
每股收益（稀释后）AVNSRGP
| Q4 25 | $-0.02 | $-0.38 | ||
| Q3 25 | $-0.03 | $-0.07 | ||
| Q2 25 | $-1.66 | $-2.21 | ||
| Q1 25 | $0.14 | $-1.34 | ||
| Q4 24 | $-8.64 | $-2.08 | ||
| Q3 24 | $0.09 | $-0.17 | ||
| Q2 24 | $0.04 | $0.31 | ||
| Q1 24 | $-0.02 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $89.8M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $194.6M |
| 总资产 | $1.1B | $289.3M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRGP
| Q4 25 | $89.8M | $89.8M | ||
| Q3 25 | $70.5M | $77.5M | ||
| Q2 25 | $90.3M | $86.1M | ||
| Q1 25 | $97.0M | $72.5M | ||
| Q4 24 | $107.7M | $78.2M | ||
| Q3 24 | $89.0M | $89.6M | ||
| Q2 24 | $92.2M | $108.9M | ||
| Q1 24 | $75.8M | $113.8M |
总债务AVNSRGP
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRGP
| Q4 25 | $778.2M | $194.6M | ||
| Q3 25 | $778.0M | $206.4M | ||
| Q2 25 | $776.3M | $207.1M | ||
| Q1 25 | $839.4M | $277.8M | ||
| Q4 24 | $828.5M | $325.7M | ||
| Q3 24 | $1.2B | $407.2M | ||
| Q2 24 | $1.2B | $418.8M | ||
| Q1 24 | $1.2B | $414.9M |
总资产AVNSRGP
| Q4 25 | $1.1B | $289.3M | ||
| Q3 25 | $1.1B | $287.2M | ||
| Q2 25 | $1.0B | $304.7M | ||
| Q1 25 | $1.1B | $375.6M | ||
| Q4 24 | $1.2B | $424.9M | ||
| Q3 24 | $1.7B | $512.9M | ||
| Q2 24 | $1.7B | $510.9M | ||
| Q1 24 | $1.7B | $523.2M |
负债/权益比AVNSRGP
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $15.6M |
| 自由现金流率自由现金流/营收 | 11.8% | 13.2% |
| 资本支出强度资本支出/营收 | 3.8% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $24.3M |
8季度趋势，按日历期对齐
经营现金流AVNSRGP
| Q4 25 | $28.2M | $15.9M | ||
| Q3 25 | $14.0M | $-7.8M | ||
| Q2 25 | $6.8M | $16.8M | ||
| Q1 25 | $25.7M | $659.0K | ||
| Q4 24 | $57.9M | $1.8M | ||
| Q3 24 | $23.0M | $-309.0K | ||
| Q2 24 | $27.8M | $3.2M | ||
| Q1 24 | $-8.0M | $20.5M |
自由现金流AVNSRGP
| Q4 25 | $21.3M | $15.6M | ||
| Q3 25 | $7.0M | $-8.0M | ||
| Q2 25 | $-4.2M | $16.5M | ||
| Q1 25 | $19.0M | $238.0K | ||
| Q4 24 | $53.1M | $61.0K | ||
| Q3 24 | $20.0M | $-575.0K | ||
| Q2 24 | $21.9M | $3.0M | ||
| Q1 24 | $-12.1M | $20.4M |
自由现金流率AVNSRGP
| Q4 25 | 11.8% | 13.2% | ||
| Q3 25 | 3.9% | -6.6% | ||
| Q2 25 | -2.4% | 11.8% | ||
| Q1 25 | 11.3% | 0.2% | ||
| Q4 24 | 29.6% | 0.0% | ||
| Q3 24 | 11.7% | -0.4% | ||
| Q2 24 | 12.8% | 2.1% | ||
| Q1 24 | -7.3% | 13.5% |
资本支出强度AVNSRGP
| Q4 25 | 3.8% | 0.3% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.3% | ||
| Q4 24 | 2.7% | 1.2% | ||
| Q3 24 | 1.8% | 0.2% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 0.1% |
现金转化率AVNSRGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
